Kornimate/medical-research-clean huggingface dataset:
neuroblastoma biology study

Conditions: Neuroblastoma

Summary: medical scientists want to find better ways to treat neuroblastoma and to find ways to prevent the tumor from growing back. to do this, they need more information about the characteristics of neuroblastoma cells. therefore, they want to study samples of neuroblastoma tissues and neuroblastoma and normal cells in the blood and bone marrow that may be related to the growth of neuroblastoma cells. doctors and other medical scientists also want to find better ways to detect and measure neuroblastoma to improve the ability to follow the response of tumor cells to therapy.

the purposes of this study are: to establish a storage place or bank of samples of blood, bone marrow, and/or tumor, and molecular components isolated from these samples from children with neuroblastoma. the stored specimens will be shared with laboratory researchers studying high risk neuroblastoma. to collect clinical data (such as treatments received, date of diagnosis, tumor stage, etc) and radiology scans to provide this information as needed for the laboratory studies to be done on the specimens. to obtain neuroblastoma tumor cells from tumor tissue, bone marrow, and/or blood to use to start cell lines, or tumor cells that will keep growing in the laboratory. these cell lines will be shared with laboratory researchers studying high risk neuroblastoma.

Eligibility criteria:
inclusion criteria: * patients must be greater than or 31 days of age. * patients must have had a diagnosis of high risk neuroblastoma either by histological verification of neuroblastoma and/or demonstration of tumor cells in the bone marrow with increased urinary catecholamines. * all patients with refractory or recurrent high risk neuroblastoma at nant institutions are eligible regardless of disease status (including no measurable or evaluable tumor) as long as they undergo a disease evaluation and appropriate samples are submitted. * additionally, all patients with high risk neuroblastoma without relapse treated at a nant institution are eligible if undergoing a disease evaluation, as long as children's oncology group specimens are prioritized. exclusion criteria: * there are no exclusion criteria on this study.
same-day combination of vi peel and botox for correction of sun damage, fine lines and wrinkles

Conditions: Photoaging; Wrinkle; Sun Damaged Skin

Summary: this study is being conducted to improve standards of care in the cosmetic treatment of sun damage, fine lines, and wrinkles. vi peels® and botox® have been used cosmetically to improve patient concerns as monotherapies. this study seeks to confirm that the same-day combination creates no additional side-effects and furthermore that patient satisfaction is heightened as a result.

this study seeks to utilize the mechanisms of action of both products to simultaneously address fine lines and wrinkles. vi peels contain a synergistic blend of acids that produce keratolytic and kerato-coagulation qualities focused on desquamation and cellular renewal. the vi peel blend contains trichloroacetic acid, phenol, salicylic acid, retinoic acid and ascorbic acid. botox containing botulinum toxin type a is a purified substance, derived from a bacterium that block muscular nerve signals temporarily preventing the muscular contraction and subsequent wrinkle formation. the expected benefit of this investigational combination include improvements to standards of care in relation to treatment of the cosmetic patient by establishing safety of the combination treatment, improving patient outcomes by simultaneously addressing sun damage, fine lines, and wrinkles through dual mechanisms, and overall improvement to patient satisfaction.

Eligibility criteria:
inclusion criteria: 1. healthy female and males subjects of any race 2. ages 30-70 years old 3. subjects who can read, understand, and sign the informed consent form. 4. subjects willing and able to comply with all study requirements, including return visits and photographs (eyes censored or uncensored). exclusion criteria: 1. is pregnant or lactating 2. has an active infection on their face (excluding acne) 3. has used isotretinoin (accutane) within the last six months 4. has had chemotherapy or radiation treatments within the last six months 5. has a history of neuromuscular disorders 6. has a history of bleeding disorders 7. has an allergy to albumin 8. has an allergy to aspirin 9. has an allergy to phenol 10. has received the following treatments in the last 6 months: botulinum toxin, soft tissue filler, medium to deep chemical peel, ablative laser, radio frequency treatment, ultrasound device treatment, non-ablative laser treatment 11. is planning on receiving in the next 1months: soft tissue filler, medium to deep chemical peel, ablative laser, radio frequency treatment, ultrasound device treatment, nonablative laser treatment 12. is unable to understand the protocol or to give informed consent 13. not willing to comply with all study requirements including return visits and photographs (eyes censored or uncensored) 14. has been diagnosed or is displaying covid-19 symptoms -

Keywords: botox vi peel wrinkles sun damage
study to investigate the pharmacokinetics & safety following one application of 3 different doses 0.5,0.75,& 1.25 gm,a transdermal estradiol cream (vml-0203), in comparison to a single dose of estrogel 1.25 gm to healthy post-menopausal women.

Conditions: Menopause

Summary: this study is a phase i, randomized, open-label, single center, cross-over study to investigate the pharmacokinetics and safety following a single application of three different doses 0.5 gm (0.5 mg estradiol), 0.75 gm (0.75 mg estradiol) and 1.25 gm (1.25 mg estradiol), a transdermal estradiol cream (vml-0203), in comparison to a single dose of estrogeltm 1.25 gm (1 unit/0.75 mg of estradiol) to healthy post-menopausal women.


Eligibility criteria:
inclusion criteria: * healthy post-menopausal (surgical or natural) female defined as: * no menstrual period within the past year before study entry. * serum estradiol levels between 0-20 pg/ml. * fsh levels greater than 25.8 miu/ml. * greater than 45 years of age or if surgical menopausal, \> 30 yrs. of age. * have a body mass index (bmi) between 18 and 30 kg/m2. have had a normal pap smear test result in line with the following guidelines: * aged 30 to 49 - within the last 3 years * aged 50 to 65 - within the last 5 years exclusion criteria: * is pregnant (urine pregnancy test at screening) or lactating. * has evidence of drug or alcohol abuse. * have used hormonal replacement or vaginal hormonal therapy within the past three months before study entry. * have used estrogen pellet therapy or progestin injectable drug therapy within the past three months before study entry. * has contraindications to hrt use, including: unexplained vaginal bleeding, liver disease, breast or endometrial cancer, venous thromboembolic events. * any subjects with an obvious presence of skin conditions, excessive hair at the application sites (no shaving), scar tissue, tattoo, or coloration that would interfere with application of imp, skin assessment, or reactions to drug. * presence of open sores at the application sites. * any subjects with a history of significant skin disorder. * smoker.

Keywords: hypoestrogenism menopausal hormone therapy
iodine nutrition status and clinical characteristics of thyroid cancer

Conditions: Thyroid Cancer

Summary: the effect of iodine nutritional status on thyroid cancer has been controversial for many years. we designed a prospective cohort study that recruiting patients in different iodine areas who underwent thyroid cancer surgery in branch hospitals from 2012 to 2019，and follow up their clinical outcomes. we aimed to analyse the relationship between regional iodine nutrition level and pathological types, clinical features, and prognosis of thyroid cancer.

three sub centers were selected in high iodine (jining/liaocheng/heze) and moderate iodine (jinan/shenyang/haerbin) areas respectively. patients lived in the above-mentioned regions for at least 5 years and diagnosed as thyroid cancer and underwent thyroid surgery in branch hospitals from 2012 to 2019 were recruited.

Eligibility criteria:
inclusion criteria: 1. age range: 18\~65 years old, gender not limited; 2. living in the selected region for at least 5 years; 3. patients who underwent thyroid surgery at various research centers were pathologically diagnosed with thyroid cancer; 4. the clinical data （general information、surgical scope 、pathological report、utrasonic report, etc ）of the case is complete. exclusion criteria: 1. diagnosed as other types of cancer or thyroid metastatic cancer; 2. there are serious comorbidities such as heart, liver, and kidney diseases present; 3. unable to follow up on prognostic information.
safety and immunogenicity of covid-19 vaccine administered in older adults

Conditions: COVID-19 Vaccine; Older Adults

Summary: the covid-19 pandemic is causing unprecedented morbidity and mortality.the safe and effective novel coronavirus vaccine is an effective means to block the transmission of the virus by building up the immune barrier of the population.clinical studies have shown that elderly people are at high risk of severe covid-19 infection and have poor clinical prognosis.considering the current situation of aging population in china, the elderly people should be given priority to vaccinate to obtain protection and reduce the risk of novel coronavirus infection.however, the current data on vaccines are mostly from young and middle-aged healthy people, while there is little research data on covid-19 vaccination in the elderly.this study mainly studied the safety and effectiveness of covid-19 vaccine in the elderly population and explored its potential immune mechanism.

this study is a prospective, multicenter, controlled , open-label and phase i clinical trial. older adults in the study included healthy people between the ages of 60 and 80 group. those who is in line with the inclusion criteria and who is not in conformity with the exclusion criteria received two doses of covid-19 vaccine at 0 days (baseline) and 21 days, respectively, and were followed up at 1, 3, 6, 9 and 12 months after completion of vaccination.

Eligibility criteria:
inclusion criteria: * a covid-19 vaccine is planned. * older adults subjects aged 60-80 years or young adults subjects aged 18-59 years. * able and willing to follow the requirements of the clinical trial protocol and complete the study follow-up for 12 months. * hbsag, anti-hcv, hiv and tpha were negative. * body temperature ≤37.0℃. exclusion criteria: * people who are allergic to any component of the vaccine, or have a serious history of vaccine allergy. * women who is pregnant, breastfeeding, or planning to be pregnant within 6 months. * sufferring serious cardiovascular diseases, such as arrhythmia, conduction block, myocardial infarction, and severe hypertension can not be well controlled by drugs. * patients with severe chronic diseases or diseases can not be controlled well during the progress, such as asthma, diabetes, thyroid disease, etc. * patients with congenital or acquired angioedema / neuroedema. * patients with lymphoma, leukemia and other systemic malignancies. * patients with convulsions, epilepsy, encephalopathy, psychiatric disorders and other progressive neurological disorders, or a family history of them. * patients with acute attack of chronic diseases. * during vaccination, immunomodulators, systemic cytotoxic drugs, immune checkpoint inhibitors (pd-1 / pdl-1 / ctla-4, etc.) and cell therapy, including nk cells, cytokine induced killer cells, dendritic cells, ctl and stem cells infusion are required. * other conditions determined by the researcher.
pre-hospital care in burn patients presenting to tertiary care centers of nepal

Conditions: Burns

Summary: this cross-sectional study investigates pre-hospital practices among burn patients presenting to a tertiary care center in nepal. it examines first aid measures, timelines to medical care, resuscitation protocols, and factors contributing to delays. findings aim to highlight gaps in burn care and inform strategies to improve patient outcomes and management practices in resource-limited settings.

burn injuries are a major public health concern in low- and middle-income countries, contributing significantly to morbidity and disability-adjusted life years (dalys) lost. this study focuses on understanding the pre-hospital care practices among burn patients in nepal, a region with limited burn care resources and high incidence rates. using structured interviews and clinical data, the study explores the type and adequacy of first aid provided, factors influencing delays in accessing tertiary care, and the effectiveness of initial resuscitation. by identifying gaps in awareness, infrastructure, and healthcare delivery, the study seeks to propose actionable recommendations for enhancing burn care systems and improving outcomes for burn patients in nepal.

Eligibility criteria:
inclusion criteria: * patients of all ages, genders, and backgrounds admitted to the study site with a primary diagnosis of burn injuries. exclusion criteria: * patients with life-threatening injuries accompanying burns. * patients with a documented history of prior burn injuries. * individuals who decline to provide informed consent.

Keywords: burn injuries burn resuscitation pre-hospital care
a study to evaluate the efficacy and safety study of povorcitinib in participants with prurigo nodularis (stop-pn1)

Conditions: Prurigo Nodularis

Summary: the purpose of this study is to evaluate effect of povorcitinib on itch and skin lesions in participants with prurigo nodularis.


Eligibility criteria:
inclusion criteria: * male and female participants 18 to 75 years of age. * clinical diagnosis of pn for at least 3 months prior to screening visit. * pruritus, defined as an average itch nrs score ≥ 7 during the 7 days prior to day 1/baseline. * total of ≥ 20 pruriginous lesions on ≥ 2 different body regions (both legs, and/or both arms, and/or trunk) at screening and day 1/baseline. * documented history of treatment failure, demonstrated intolerance, or contraindication to a previous pn treatment. * willingness to avoid pregnancy or fathering children. exclusion criteria: * chronic pruritus due to a condition other than pn or neuropathic and psychogenic pruritus. * diagnosis of pn secondary to medications. * active ad lesions (signs and symptoms other than dry skin) within 3 months prior to screening visit. * women who are pregnant (or are considering pregnancy) or breastfeeding. * medical history including thrombocytopenia, coagulopathy or platelet dysfunction; venous and arterial thrombosis, deep vein thrombosis, pulmonary embolism, stroke, moderate to severe heart failure, cerebrovascular accident, myocardial infarction, or other significant cardiovascular diseases; q-wave interval abnormalities; disseminated herpes zoster or dermatomal herpes zoster; disseminated herpes simplex; chronic/recurrent infections; malignancies. * evidence of infection with tb, hbv, hcv or hiv. * history of failure to any topical or systemic jak or tyk2 inhibitor as treatment of pn or any inflammatory disease. * laboratory values outside of the protocol-defined ranges. other protocol-defined inclusion/exclusion criteria apply.

Keywords: prurigo nodularis pn incb054707 chronic pruritus
relative bioavailability of meloxicam 2 x 7.5 mg tablets compared to 15 mg tablet and dose proportionality over a dose range of 7.5 mg and 15 mg in healthy volunteers

Conditions: Healthy

Summary: study to assess the relative bioavailability of two 7.5 mg meloxicam tablets (american type) compared to one 15 mg meloxicam tablet (american type), and to investigate dose-proportionality over the dosage range 7.5 mg to 15 mg


Eligibility criteria:
inclusion criteria: * healthy subjects as determined by results of screening * written informed consent in accordance with good clinical practice (gcp) and local legislation * age \>= 18 and \<= 50 years * broca \>= -20% and \<= + 20 % exclusion criteria: * any finding of the medical examination (including laboratory blood pressure, pulse rate and ecg) deviating from normal and of clinical relevance * gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders * surgery of the gastro-intestinal tract (except appendectomy) * diseases of the central nervous system (such as epilepsy) or psychiatric disorders * chronic or relevant acute infections * hypersensitivity to meloxicam and/or non-steroidal antirheumatic agents * intake of drugs with a long half-life (\>24 hours) (\<= 1 month prior to administration or during the trial) * use of any drugs which might influence the results of the trial (\<= 10 days prior to administration or during the trial) * participation in another trial with an investigational drug (\<= 2 months prior to administration or during the trial) * smoker (\>= 10 cigarettes or \>= 3 cigars or \>= 3 pipes/day) * inability to refrain from smoking on study days * alcohol abuse * drug abuse * blood donation (\<= 1 months prior to administration) * excessive physical activities (\<= 5 days prior to administration) * history of hemorrhagic diatheses * history of gastro-intestinal ulcer, perforation or bleeding * history of bronchial asthma for female subjects: * pregnancy * positive pregnancy test * no adequate contraception e.g. sterilization, intrauterine device (iud), oral contraceptives * inability to maintain this adequate contraception during the whole study period * lactating
three measures for the prevention of carious lesions in preschool children

Conditions: Dental Caries

Summary: analysis different measures preventive effect on carious lesions incidence and oral microecological system change of preschool children

different caries prevention trials including fluoride vanish, igy-passive immunotherapy and probiotics lasting 24 months were conducted with a total of 500 children aged 24 to 54 months of age in lin'an, zhejiang, china. the trials were cluster- domized .after obtaining parent´s informed consent, preschool children were clinical examinated according to icdas-ⅱ and microbiological tested of saliva at baseline, 1m, 6m, 12m, 18m and 24m. to find the differences of caries incidence and oral microecology change in four groups, dmfs will be assessed and saliva will be analysed in experiment.

Eligibility criteria:
inclusion criteria: * preschool children in good general health * at least 18 deciduous teeth exclusion criteria: * with major systemic disease or on long-term medication * not cooperative and refuse dental treatment * with a history of extra fluoride supplement * take antibiotics for nearly 8 weeks
prevention of transmission of sexually transmitted diseases in the youth through effective intervention,

Conditions: HIV

Summary: the data of taiwan cdc showed the total hiv victims amounted up to 22,020 from 1984 to 2011. under risk factor analysis, it indicated the increasing victims among msm (men having sex with men, including homosexuals \& bisexuals) cohorts, from 64% of them in 2009 to 72% in 2011. for age stratification of patients, the youth (from 15 to 24 years old) comprised of 18.5% (4078). among them, 40% are students. msm are still the main population (over 80%) from 2009 to 2011. therefore it is crucial to target the young msm.

purpose: under the hospital based, and in conjuction with the community, we try to target the young hiv msm victims and develop the partnership networking to seek for the potential high risk couples to enroll into our intervention. materials \& methods: at hospital, though hiv clinic has case manager, however the limitation of space and privacy, we just focus on the hiv patient itself and have limited time to educate patients' sex partners. therefore, we aimed at enrolling more of the intimate partners thru young hiv msm victims thru hospital base. we will provide the saliva oraquick rapid test service to the partners, thus set up the relationship with the study subjects, and then communicate with them and educate them with knowledge of sexual transmitted diseases and sex health. we plan to enroll 200 study subjects till the end of this year. our co-pi, prof. y.m. chen will also perform hiv gene clustering analysis thru high throughput ultra-deep pyrosequencing among young msm hiv victims. the other co-pi prof. p.i. chou will train the research assistant adopting msm hiv victim partner follow-up model to approach the study subjects with structured questionnaires. prof. chou also collected the study subjects in the northern taiwan with her own project, thus we can compare and analyze the difference from the locality (north area v.s. south area). anticipated work: we aim at enrolling 300 young hiv msm partners to this oraquick rapid test, setting up the follow-up model and providing the intervention education of safe sex thru individual case management, group meeting, leader-finding plan and interactive msm web networking to achieve the preventione of sexual disease transmission in the youth.

Eligibility criteria:
inclusion criteria: 1. homosexual or bisexual and msm who have sex. 2. age over 15 years old to 30 years old. exclusion criteria: 1. women and heterosexual. 2. aids was received within three months of screening those.
amd3100 plus mitoxantrone, etoposide and cytarabine in acute myeloid leukemia

Conditions: Leukemia, Myeloid, Acute

Summary: this study is a phase i/ii study to determine the safety and efficacy of amd3100 when combined with mitoxantrone, etoposide, and cytarabine in patients with relapsed or refractory aml. we hypothesize that disrupting the interaction between aml blasts and the marrow microenvironment with amd3100 may enhance the cytotoxic effect of chemotherapy.

the interaction of leukemic blasts with the bone marrow microenvironment is postulated to be an important mediator of chemoresistance in aml. although a number of receptor / ligand pairs have been implicated, the cxcr4 / sdf-1 axis functions as the principal regulator of homing and retention of both normal and malignant hematopoietic cells in the marrow. amd3100 is a bicyclam molecule which reversibly blocks cxcr4 binding to sdf-1 and is being developed clinically as a mobilization agent for hematopoietic stem cell transplantation. preclinical data from our group has demonstrated that in murine models, plerixafor can disrupt the interaction of leukemic cells with the marrow microenvironment and sensitize blasts to the effect of chemotherapy. based on these data, we have initiated a phase i/ii study in patients with relapsed or refractory aml in which plerixafor is administered prior to salvage chemotherapy.

Eligibility criteria:
inclusion criteria: 1. acute myeloid leukemia diagnosed by who criteria with one of the following: 1. primary refractory disease following \>= 1 rounds of induction chemotherapy 2. first relapse or higher 2. age between 18 and 70 years of age 3. adequate organ function defined as creatinine \ = 40% by muga scan 4. women of childbearing potential and sexually active males must be willing and able to use effective contraception while on study 5. able to provide signed informed consent prior to registration on study exclusion criteria: 1. acute promyelocytic leukemia (aml with t(15;17)(q22;q11) and variants) 2. peripheral blood blast count \> 20 x 103 /mm3 3. active cns involvement with leukemia 4. previous treatment with mec or other regimen containing both mitoxantrone and etoposide 5. pregnant or nursing 6. receiving any other investigational agent 7. colony stimulating factors filgrastim, pegfilgrastim or sargramostim within 2 weeks of study 8. less than 2 weeks from the completion of any previous cytotoxic chemotherapy 9. severe concurrent illness that would limit compliance with study requirements

Keywords: plerixafor cxcr4 chemosensitization